Text
In our recent article [1], we did not declare the patent rights related to stampidine technology. Since they may potentially be viewed as non-financial competing interests despite the fact our employer is a non-profit public charity, we are now providing the following supplemental information:
FMU, AOV and HET are employees of Parker Hughes Institute, which has applied for a patent for the use of stampidine in the treatment of haemorrhagic fever. Parker Hughes Institute currently holds patents for the use of stampidine in other clinical conditions, with FMU listed as an inventor.
Pre-publication history
The pre-publication history for this paper can be accessed here:
Contributor Information
Fatih M Uckun, Email: fatih_uckun@ih.org.
Alexander S Petkevich, Email: asp@briem.ac.by.
Alexei O Vassilev, Email: avassilev@ih.org.
Heather E Tibbles, Email: htibbles@ih.org.
Leonid Titov, Email: briem@hmti.ac.by.
References
- Uckun FU, Petkevich AS, Vassilev AO, Tibbles HE, Titov LP. Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. BMC Infect Dis. 2004;4:1. doi: 10.1186/1471-2334-4-1. [DOI] [PMC free article] [PubMed] [Google Scholar]